Transcriptome level analysis in Rett syndrome using human samples from different tissues
暂无分享,去创建一个
[1] Jonathan Pevsner,et al. FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. , 2007, Human molecular genetics.
[2] James C. Cronk,et al. Wild type microglia arrest pathology in a mouse model of Rett syndrome , 2012, Nature.
[3] A. Bird,et al. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. , 1993, Nucleic acids research.
[4] James C. Cronk,et al. The role of microglia in brain maintenance: implications for Rett syndrome. , 2013, Trends in immunology.
[5] David A. Orlando,et al. Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. , 2013, Cell stem cell.
[6] G. Valacchi,et al. Genes Related to Mitochondrial Functions, Protein Degradation, and Chromatin Folding Are Differentially Expressed in Lymphomonocytes of Rett Syndrome Patients , 2013, Mediators of inflammation.
[7] G. Ananiev,et al. Isogenic Pairs of Wild Type and Mutant Induced Pluripotent Stem Cell (iPSC) Lines from Rett Syndrome Patients as In Vitro Disease Model , 2011, PloS one.
[8] O. Dreesen,et al. Unexpected X chromosome skewing during culture and reprogramming of human somatic cells can be alleviated by exogenous telomerase. , 2011, Cell stem cell.
[9] Katharina Dietrich,et al. Systemic Radical Scavenger Treatment of a Mouse Model of Rett Syndrome: Merits and Limitations of the Vitamin E Derivative Trolox , 2016, Front. Cell. Neurosci..
[10] N. Kaya,et al. Genomic and transcriptomic analyses distinguish classic Rett and Rett-like syndrome and reveals shared altered pathways. , 2011, Genomics.
[11] H. Zoghbi,et al. Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome , 2008, Neurology.
[12] B. Antalffy,et al. Decreased Dendritic Branching in Frontal, Motor and Limbic Cortex in Rett Syndrome Compared with Trisomy 21 , 1998, Journal of neuropathology and experimental neurology.
[13] E. Schon,et al. Neuronal degeneration and mitochondrial dysfunction. , 2003, The Journal of clinical investigation.
[14] T. E. Morgan,et al. Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro , 2005, Journal of neurochemistry.
[15] K. Jellinger,et al. Neuropathology of Rett syndrome. , 1988, Acta neuropathologica.
[16] Paul H Lerou,et al. Generation of human-induced pluripotent stem cells , 2008, Nature Protocols.
[17] S. Nelson,et al. Cell-Type-Specific Repression by Methyl-CpG-Binding Protein 2 Is Biased toward Long Genes , 2014, The Journal of Neuroscience.
[18] J. Christodoulou,et al. Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain , 2010, BMC Neuroscience.
[19] G. Mandel,et al. MeCP2 Is Critical for Maintaining Mature Neuronal Networks and Global Brain Anatomy during Late Stages of Postnatal Brain Development and in the Mature Adult Brain , 2012, The Journal of Neuroscience.
[20] A. Bird,et al. Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes , 2016, Human molecular genetics.
[21] J. Arunachalam,et al. MeCP2270 Mutant Protein Is Expressed in Astrocytes as well as in Neurons and Localizes in the Nucleus , 2010, Cytogenetic and Genome Research.
[22] A. Scheibel,et al. Neuropathology of Rett Syndrome: Case Report With Neuronal and Mitochondrial Abnormalities in the Brain , 1994, Journal of child neurology.
[23] Eric P. Hoffman,et al. Gene Expression Profiling in Postmortem Rett Syndrome Brain: Differential Gene Expression and Patient Classification , 2001, Neurobiology of Disease.
[24] S. Skinner,et al. Rett Syndrome: North American Database , 2007, Journal of child neurology.
[25] J B Schulz,et al. Glutathione, oxidative stress and neurodegeneration. , 2000, European journal of biochemistry.
[26] T. Matsuishi,et al. Alterations of Gene Expression and Glutamate Clearance in Astrocytes Derived from an MeCP2-Null Mouse Model of Rett Syndrome , 2012, PloS one.
[27] D. Armstrong,et al. The neuropathology of the Rett syndrome. , 1992, Brain & development.
[28] M. Rastegar,et al. Brain Region-Specific Expression of MeCP2 Isoforms Correlates with DNA Methylation within Mecp2 Regulatory Elements , 2014, PloS one.
[29] J. Opitz,et al. Rett syndrome: genetic clues based on mitochondrial changes in muscle. , 1989, American journal of medical genetics.
[30] G. Valacchi,et al. Systemic oxidative stress in classic Rett syndrome. , 2009, Free radical biology & medicine.
[31] David P. Kreil,et al. The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance , 2014, Nature Biotechnology.
[32] R. Gambari,et al. Cytokines profile and peripheral blood mononuclear cells morphology in Rett and autistic patients. , 2016, Cytokine.
[33] W. Kaufmann,et al. Rett syndrome: Revised diagnostic criteria and nomenclature , 2010, Annals of neurology.
[34] G. Valacchi,et al. Scavenger receptor B1 post‐translational modifications in Rett syndrome , 2013, FEBS letters.
[35] W. Kaufmann,et al. Selective Cerebral Volume Reduction in Rett Syndrome: A Multiple-Approach MR Imaging Study , 2008, American Journal of Neuroradiology.
[36] C. Masters,et al. Rett syndrome: abnormal membrane-bound lamellated inclusions in neurons and oligodendroglia. , 1988, American journal of medical genetics.
[37] W. Kaufmann,et al. MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution , 2005, Brain and Development.
[38] J. Pronk,et al. Reproducibility of Oligonucleotide Microarray Transcriptome Analyses , 2002, The Journal of Biological Chemistry.
[39] A. Bittner,et al. Comparison of RNA-Seq and Microarray in Transcriptome Profiling of Activated T Cells , 2014, PloS one.
[40] A. Bird,et al. MeCP2 Is a Transcriptional Repressor with Abundant Binding Sites in Genomic Chromatin , 1997, Cell.
[41] Meredith Wilson,et al. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy , 2012, European Journal of Human Genetics.
[42] G. Cevenini,et al. Diagnostic criteria for the Zappella variant of Rett syndrome (the preserved speech variant) , 2009, Brain and Development.
[43] S. Coker,et al. Rett Syndrome and Mitochondrial Enzyme Deficiencies , 1991, Journal of child neurology.
[44] S. Kudo. Methyl-CpG-Binding Protein MeCP2 Represses Sp1-Activated Transcription of the Human Leukosialin Gene When the Promoter Is Methylated , 1998, Molecular and Cellular Biology.
[45] Huan Wang,et al. Neuronal Interleukin-4 as a Modulator of Microglial Pathways and Ischemic Brain Damage , 2015, The Journal of Neuroscience.
[46] H. Zoghbi,et al. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. , 2002, Human molecular genetics.
[47] D. Harvey,et al. Rett Syndrome Astrocytes Are Abnormal and Spread MeCP2 Deficiency through Gap Junctions , 2009, The Journal of Neuroscience.
[48] L. Pozzo-Miller,et al. Dendritic spine dysgenesis in Rett syndrome , 2014, Front. Neuroanat..
[49] A. Bird,et al. DNA methylation specifies chromosomal localization of MeCP2 , 1996, Molecular and cellular biology.
[50] Michael J. Yetman,et al. Wild-type microglia do not reverse pathology in mouse models of Rett syndrome , 2015, Nature.
[51] A. Reiss,et al. Neuroanatomy of Rett syndrome: A volumetric imaging study , 1993, Annals of neurology.
[52] H. Zoghbi,et al. Karyopherin α 3 and Karyopherin α 4 Proteins Mediate the Nuclear Import of Methyl-CpG Binding Protein 2* , 2015, The Journal of Biological Chemistry.
[53] H. Zoghbi,et al. Brief Report: MECP2 Mutations in People Without Rett Syndrome , 2014, Journal of autism and developmental disorders.
[54] Noriyuki Kishi,et al. MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions , 2004, Molecular and Cellular Neuroscience.
[55] W. Kaufmann,et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome , 2014, Journal of Medical Genetics.
[56] J. Rothstein,et al. Glutamate transporter expression and function in human glial progenitors , 2004, Glia.
[57] S. Ojeda,et al. Correcting deregulated Fxyd1 expression ameliorates a behavioral impairment in a mouse model of Rett syndrome , 2013, Brain Research.
[58] K. Gordon,et al. Male Rett syndrome variant: application of diagnostic criteria. , 1999, Pediatric neurology.
[59] Thomas Sommer,et al. Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system. , 2014, Biochimica et biophysica acta.
[60] J. Raber,et al. A role for glia in the progression of Rett’s syndrome , 2011, Nature.
[61] Christina Thaller,et al. Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus , 2009, Human molecular genetics.
[62] H. Sarnat. Clinical neuropathology practice guide 5-2013: markers of neuronal maturation , 2013, Clinical neuropathology.
[63] David P. Kreil,et al. A comprehensive study design reveals treatment-and transcript abundance – dependent concordance between RNA-seq and microarray data , 2014 .
[64] P. Fisher,et al. Role of Excitatory Amino Acid Transporter‐2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics , 2011, Journal of cellular physiology.
[65] Sherman Morton Weissman,et al. Transcriptional regulation in pluripotent stem cells by methyl CpG-binding protein 2 (MeCP2). , 2014, Human molecular genetics.
[66] R. Edwards,et al. Transcriptome analysis of human brain tissue identifies reduced expression of complement complex C1Q Genes in Rett syndrome , 2016, BMC Genomics.
[67] A. Antonietti,et al. Recent insights into genotype-phenotype relationships in patients with Rett syndrome using a fine grain scale. , 2014, Research in developmental disabilities.
[68] S. Melov,et al. Mitochondrial disease in mouse results in increased oxidative stress. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[69] E. Masliah,et al. Widespread changes in dendritic and axonal morphology in Mecp2‐mutant mouse models of rett syndrome: Evidence for disruption of neuronal networks , 2009, The Journal of comparative neurology.
[70] A. Bird,et al. Gene Expression Analysis Exposes Mitochondrial Abnormalities in a Mouse Model of Rett Syndrome , 2006, Molecular and Cellular Biology.
[71] F. Bianchi,et al. Rett syndrome: a wide clinical and autonomic picture , 2016, Orphanet Journal of Rare Diseases.
[72] J. Strouboulis,et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription , 1998, Nature Genetics.
[73] H. Okano,et al. Differentiation of multipotent neural stem cells derived from Rett syndrome patients is biased toward the astrocytic lineage , 2015, Molecular Brain.
[74] Martin J. Aryee,et al. Epigenetic memory in induced pluripotent stem cells , 2010, Nature.
[75] J Dragich,et al. Rett syndrome: a surprising result of mutation in MECP2. , 2000, Human molecular genetics.
[76] David Baltimore,et al. NF-κB functions in synaptic signaling and behavior , 2003, Nature Neuroscience.
[77] M. D'Esposito,et al. Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome , 2014, Neurobiology of Disease.
[78] B. Hagberg,et al. "Forme fruste" of Rett syndrome--a case report. , 1986, American journal of medical genetics. Supplement.
[79] S. Kyrylenko,et al. Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells , 2005, Neurochemistry International.
[80] L. Opitz,et al. Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome , 2012, Neurobiology of Disease.
[81] Marianna Aprile,et al. RNA-Seq and human complex diseases: recent accomplishments and future perspectives , 2012, European Journal of Human Genetics.
[82] P. Huppke,et al. MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. , 2001, American journal of human genetics.
[83] M. D'Esposito,et al. Increased levels of 4HNE-protein plasma adducts in Rett syndrome. , 2011, Clinical biochemistry.
[84] Fred H. Gage,et al. A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells , 2010, Cell.
[85] Tianlin Cheng,et al. Conditional deletion of Mecp2 in parvalbumin-expressing GABAergic cells results in the absence of critical period plasticity , 2014, Nature Communications.
[86] George Perry,et al. Oxidative Stress and Neurodegeneration , 2005, Annals of the New York Academy of Sciences.
[87] J. Christodoulou,et al. Rett Syndrome: A Genetic Update and Clinical Review Focusing on Comorbidities. , 2017, ACS chemical neuroscience.
[88] M. Fagiolini,et al. Visual evoked potentials detect cortical processing deficits in Rett syndrome , 2015, Annals of neurology.
[89] B. Hagberg. Clinical manifestations and stages of Rett syndrome. , 2002, Mental retardation and developmental disabilities research reviews.
[90] G. Mandel,et al. Non–cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology , 2009, Nature Neuroscience.
[91] L. Carrel,et al. X-Chromosome Inactivation in Rett Syndrome Human Induced Pluripotent Stem Cells , 2012, Front. Psychiatry.
[92] J. Charrow,et al. Increased Wnt and Notch signaling: a clue to the renal disease in Schimke immuno-osseous dysplasia? , 2016, Orphanet Journal of Rare Diseases.
[93] R. Weksberg,et al. Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation , 2011, Human molecular genetics.
[94] J. Galano,et al. Cytokine Dysregulation in MECP2- and CDKL5-Related Rett Syndrome: Relationships with Aberrant Redox Homeostasis, Inflammation, and ω-3 PUFAs , 2015, Oxidative medicine and cellular longevity.
[95] K. Hochedlinger,et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells , 2010, Nature Biotechnology.
[96] Izumi Maezawa,et al. Rett Syndrome Microglia Damage Dendrites and Synapses by the Elevated Release of Glutamate , 2010, The Journal of Neuroscience.
[97] B. Molyneaux,et al. Reduction of aberrant NF-κB signalling ameliorates Rett syndrome phenotypes in Mecp2-null mice , 2016, Nature Communications.
[98] H. Leonard,et al. Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome , 2016, Orphanet Journal of Rare Diseases.
[99] D. Butterfield,et al. Oxidative stress and neurodegeneration , 2017, Brain Research Bulletin.
[100] J Christodoulou,et al. Refining the phenotype of common mutations in Rett syndrome , 2004, Journal of Medical Genetics.
[101] R. Cantor,et al. Phenotypic manifestations of MECP2 mutations in classical and atypical rett syndrome , 2004, American journal of medical genetics. Part A.
[102] J. Christodoulou,et al. RettBASE: Rett syndrome database update , 2017, Human mutation.
[103] J. Tolmie,et al. CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients , 2006, Journal of Medical Genetics.
[104] T. Hasegawa,et al. A 2.0 Mb microdeletion in proximal chromosome 14q12, involving regulatory elements of FOXG1, with the coding region of FOXG1 being unaffected, results in severe developmental delay, microcephaly, and hypoplasia of the corpus callosum. , 2013, European journal of medical genetics.